Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Clinical Efficacy of Calcium and Sodium Phosphosilicate (Novamin) in the Treatment of MIH (Molar Incisor Hypolimineralization) in Pediatric Patients

NCT06396988 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-05-15
Last updated
2024-06-18

Condition(s) studied

Molar Incisor Hypomineralization

Investigational drug(s) / intervention(s)

Novamin applicationParodontax application

Novamin application: Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).

Parodontax application: Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).

Study summary

The aim of the following study is to evaluate the clinical efficacy of a toothpaste with calcium and sodium phosphosilicate in the treatment of demineralization of the dental enamel of molars and incisors in pediatric patients. Patients who agree to participate to the study will use 2 different toothpaste Sensodyne Repair and Protect and Parodontax, which will used with split mouth design. The following indices will be measured: BEWE, Bleeding Index, Gingival Index, Plaque Index, Dental sensitivity test- Schiff, Pain Intensity Index- VAS and PPD.

Eligibility

Sex
ALL
Min age
7 Years
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: * Presence of at least 2 demineralizations of the dental enamel of molars and incisors (molar incisor hypomineralization-MIH) on contralateral permanent teeth * Patients with mild or moderate MIH * Good general health (absence of particular systemic pathologies) Exclusion Criteria: * Patients undergoing orthodontic therapy * Patients taking drugs * Patients with severe MIH (tooth surface with defect \> 2/3, post-eruptive enamel breakage)

Primary outcome measure(s)

  • Change in Bleeding Index — Study begin, 1, 3, 6, 9, 12 months
    0: absence of bleeding after 30 seconds 1. bleeding observed after 30 seconds 2. immediate bleeding
  • Change in Gingival Index — Study begin, 1, 3, 6, 9, 12 months
    0: normal gingiva 1. mild inflammation, edema and swelling, no bleeding 2. moderate inflammation with edema, sweelling and bleeding on probing 3. severe inflammation with marked edema, redness tissues, ulceration and spontaneous bleeding
  • Change in Plaque Control Record — Study begin, 1, 3, 6, 9, 12 months
    The index is calculated multiplying the total number of surfaces with plaque per 100
  • Change in Schiff Air Index — Study begin, 1, 3, 6, 9, 12 months
    0: the subject did not respond to air blasting 1. the subject responded to air blasting 2. the subject responded to air blasting and requested discontinuation 3. the subject responded to air blasting, requested discontinuation and considered the stimulus to be painful
  • Change in Basic Erosive Wear Examination — Study begin, 1, 3, 6, 9, 12 months
    0: no erosive tooth wear 1. initial loss of surface texture 2. distinct defect, hard tissue loss \< 50% of the surface area 3. hard tissue loss ≥ 50% of the surface area
  • Change in Wong- Backer faces pain rating scales — Study begin, 1, 3, 6, 9, 12 months
    0-1: no pain 1-2: milde pain 3-4: moderate pain 5-6: acute pain 7-8: very severe pain 9-10: unbearable pain

Trial sites (1)

FacilityCityRegionStatus
Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia Pavia Lombardy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06396988 on ClinicalTrials.gov ↗ ← All trials in Italy